.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,169,765

« Back to Dashboard

Details for Patent: 7,169,765

Title:Acyl deoxyribonucleoside derivatives and uses thereof
Abstract: The invention relates to compositions comprising acyl derivatives of 2'-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced biological damage, and methods for improving wound healing and tissue repair, comprising administering the compositions of the present invention to an animal.
Inventor(s): Von Borstel; Reid W. (Kensington, MD), Bamat; Michael K. (Potomac, MD)
Assignee: Wellstat Therapeutics Corporation (Gaithersburg, MD)
Filing Date:Jan 31, 2000
Application Number:09/494,243
Claims:1. A method for treating mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an acyl derivative of 2'-deoxyadenosine, having the formula ##STR00019## wherein R.sub.1, R.sub.2, and R.sub.3 are the same or different and each is hydrogen or an acyl group derived from (a) an unbranched fatty acid with 3 to 22 carbon atoms, (b) an amino acid selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, and ornithine, (c) nicotinic acid, or (d) a dicarboxylic acid having 3 to 22 carbon atoms, provided that not all of R.sub.1, R.sub.2, and R.sub.3 are H, and where R.sub.3 is not H, then R.sub.1 and/or R.sub.2 may also be acetyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

2. A method for treating mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an acyl derivative of 2'-deoxyguanosine having the formula ##STR00020## wherein R.sub.1, R.sub.2, and R.sub.3 are the same or different and each is hydrogen or an acyl group derived from (a) an unbranched fatty acid with 3 to 22 carbon atoms, (b) an amino acid selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, phenylalanine, carnitine, and ornithine, (c) nicotinic acid, or (d) a dicarboxylic acid having 3 to 22 carbon atoms, provided that not all of R.sub.1, R.sub.2, and R.sub.3 are H, and where R.sub.3 is not H, then R.sub.1 and/or R.sub.2 may also be acetyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A method for treating mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an acyl derivative of 2'-deoxycytidine, having the formula ##STR00021## wherein R.sub.1, R.sub.2, and R.sub.3 are the same or different and each is hydrogen or an acyl group derived from (a) an unbranched fatty acid with 3 to 22 carbon atoms, (b) an amino acid selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, and ornithine, (c) nicotinic acid, or (d) a dicarboxylic acid having 3 to 22 carbon atoms, provided that not all of R.sub.1, R.sub.2, and R.sub.3 are H, and where R.sub.3 is not H, then R.sub.1 and/or R.sub.2 may also be acetyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A method for treating mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an acyl derivative of 2'-deoxythymidine, having the formula ##STR00022## wherein R.sub.1 is an acyl group derived from (a) an unbranched fatty acid with 3 to 15 or 17 to 22 carbon atoms, (b) an amino acid selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, and ornithine, (c) nicotinic acid, or (d) a dicarboxylic acid having 3 to 22 carbon atoms, and R.sub.2 and R.sub.3 are H, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. A method for treating mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an acyl derivative of 2'-deoxythymidine, having the formula ##STR00023## wherein R.sub.1 is H, R.sub.2 is an acyl group derived from (a) an unbranched fatty acid with 3 to 13 or 15 to 22 carbon atoms, (b) an amino acid selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, and ornithine, (c) nicotinic acid, or (d) a dicarboxylic acid with 3 to 22 carbon atoms, and R.sub.3 is H or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6. A method for treating mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an acyl derivative of 2'-deoxythymidine, having the formula ##STR00024## wherein R.sub.1 and R.sub.2 are the same or different and each is an acyl group derived from (a) an unbranched fatty acid with 5 to 22 carbon atoms, (b) an amino acid selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, and ornithine, (c) nicotinic acid, or (d) a dicarboxylic acid with 3 to 22 carbon atoms, and R.sub.3 is H or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A method for treating a mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an acyl derivative of 2'-deoxythymidine, having the formula ##STR00025## wherein R.sub.1 and R.sub.2 are the same or different and each is an acyl group derived from (a) an unbranched fatty acid with 2 to 22 carbon atoms, (b) an amino acid selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, tyrosine, proline, hydroxyproline, serine, threonine, cysteine, aspartic acid, glutamic acid, arginine, lysine, histidine, carnitine, and ornithine, (c) nicotinic acid or (d) a dicarboxylic acid with 3 to 22 carbon atoms, and R.sub.3 is an acyl group derived from an optionally substituted benzoyl or heterocyclic carboxylic acid that is substantially nontoxic, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A method for treating a mutagen-induced cellular damage in an animal comprising administering to an animal in need thereof an effective amount of a composition comprising an effective amount of each of at least two compounds selected from at least two of the groups of compounds having formulae ##STR00026## wherein R.sub.1, R.sub.2, and R.sub.3 are the same or different and each is H or an acyl group derived from a carboxylic acid, provided that at least one of said substituents R.sub.1, R.sub.2, and R.sub.3 on each of said groups of compounds is not hydrogen, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc